Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.
Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, Marmé F, Müller T, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Zahm DM, Thill M, Golatta M, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Reimer T, et al. Among authors: veselinovic k. N Engl J Med. 2024 Dec 12. doi: 10.1056/NEJMoa2412063. Online ahead of print. N Engl J Med. 2024. PMID: 39665649
Topical treatment of chemotherapy-induced peripheral neuropathy (CIPN) with high-concentration (179 mg) capsaicin patch in breast cancer patients - results of the QUCIP study.
Lux MP, Flöther L, Frömter C, Rack B, Veselinovic K, Heine M, Paepke S, Krabisch P, Quandel T, Sabatowski R. Lux MP, et al. Among authors: veselinovic k. Front Oncol. 2024 Sep 6;14:1452099. doi: 10.3389/fonc.2024.1452099. eCollection 2024. Front Oncol. 2024. PMID: 39309732 Free PMC article.
Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast Centers.
Schäffler H, Jakob D, Huesmann S, Pfister K, Veselinovic K, Schochter F, Leinert E, Fink V, Rack B, Englisch A, Volmer LL, Engler T, Frevert ML, Juhasz-Böss I, Brucker S, Heublein S, Janni W, Taran FA, Hartkopf A, Dannehl D. Schäffler H, et al. Among authors: veselinovic k. Geburtshilfe Frauenheilkd. 2024 Sep 2;84(9):855-865. doi: 10.1055/a-2375-5194. eCollection 2024 Sep. Geburtshilfe Frauenheilkd. 2024. PMID: 39229630 Free PMC article.
Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials.
Dayan D, Lukac S, Rack B, Ebner F, Fink V, Leinert E, Veselinovic K, Schütze S, El Taie Z, Janni W, Friedl TWP. Dayan D, et al. Among authors: veselinovic k. Breast Cancer Res. 2023 Dec 14;25(1):153. doi: 10.1186/s13058-023-01750-0. Breast Cancer Res. 2023. PMID: 38098086 Free PMC article.
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers.
Schäffler H, Mergel F, Pfister K, Lukac S, Fink A, Veselinovic K, Rack B, Fink V, Leinert E, Dimpfl M, Englisch A, Tegeler CM, Seller A, Grischke EM, Hahn M, Volmer LL, Engler T, Frevert ML, Taran FA, Janni W, Brucker SY, Hartkopf AD, Dannehl D. Schäffler H, et al. Among authors: veselinovic k. Int J Mol Sci. 2023 Nov 15;24(22):16366. doi: 10.3390/ijms242216366. Int J Mol Sci. 2023. PMID: 38003555 Free PMC article.
Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer-Real-World Data from Two Large German Breast Centers.
Dannehl D, Engler T, Volmer LL, Tegeler CM, Fusshoeller J, Gabrysch E, Eissler K, Seller A, Grischke EM, Hahn M, Gruber I, Schochter F, Pfister K, Veselinovic K, Leinert E, Rack B, Fink V, Janni W, Brucker SY, Hartkopf AD, Schäffler H. Dannehl D, et al. Among authors: veselinovic k. Cancers (Basel). 2023 Jul 28;15(15):3847. doi: 10.3390/cancers15153847. Cancers (Basel). 2023. PMID: 37568663 Free PMC article.
12 results